Back to Journals » Journal of Multidisciplinary Healthcare » Volume 13

The Prevalence of Sarcopenic Obesity in Postmenopausal Women with a History of Breast Cancer Depending on Adopted Methodology – A Case–Control Study

Authors Kałędkiewicz E, Milewska M, Panczyk M, Szostak-Węgierek D

Received 6 August 2020

Accepted for publication 22 September 2020

Published 27 November 2020 Volume 2020:13 Pages 1749—1758

DOI https://doi.org/10.2147/JMDH.S274660

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser


Emilia Kałędkiewicz,1 Magdalena Milewska,1 Mariusz Panczyk,2 Dorota Szostak-Węgierek1

1Department of Clinical Dietetics, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland; 2Department of Education and Research in Health Sciences, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland

Correspondence: Emilia Kałędkiewicz Email emilia.kaledkiewicz@wum.edu.pl

Introduction: Sarcopenic obesity (SO) is characterized as the cooccurrence of sarcopenia and obesity. It is associated with many adverse health consequences, also in oncological patients. The study aimed to assess the prevalence of SO in postmenopausal women with a history of breast cancer depending on adopted methodology.
Materials and Methods: The case–control study enrolled 103 women over the age of 50 with a history of breast cancer, including women who completed oncological treatment and had remained in remission for at least 5 years (group I, n=78) and women in whom the disease recurred (group II, n=25). The control group included women with no history of breast cancer (group III, n=73).
Results: In group II sarcopenia occurred significantly more commonly compared to both group I and the control group (for the skeletal muscle index (SMI) ≤ 29.20%: 13 (52%) in group II vs 16 (20.5%) in group I, p=0.004 and 3 (4.1%) in group III, p< 0.001; for SMI ≤ 26.60%: 10 (40%) in group II vs 9 (11.5%) in group I, p=0.003 and 3 (4.1%) in group III, p< 0.001; for SMI ≤ 33.87%: 17 (68%) in group II vs 21 (26.9%) in group I, p< 0.001 and 5 (6.8%) in group III, p< 0.001). Depending on the assessment criteria, SO was diagnosed in 0– 11.5% of cases in group I, 0– 40% of cases in group II and 0– 4.1% in the control group. Intergroup differences were not statistically significant, irrespective of the adopted pair of diagnostic criteria. The highest detectability of SO was observed when SMI was combined with each of the diagnostic criteria for obesity used.
Discussion: SO diagnosis based on the percentage of fatty tissue mass in the body of > 38% and SMI value were associated with a higher detection rate of SO in each study group, regardless of the adopted cut-off value. Similar results were obtained in each analyzed group when using the remaining diagnostic criteria for obesity and SMI value, regardless of the cut-off value.

Keywords: sarcopenia, obesity, breast neoplasms, muscles, menopause, aging

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]